The Vaccine Platform

Hawaii Biotech’s protein production platform for developing vaccines targeting numerous infectious diseases is particularly well suited to meet the multiple requirements of safety, production yield, rapid response, and efficacy.

The Company’s vaccine technology is based on the production of recombinant proteins using stable insect cell lines. The high quality of the proteins produced in this system results in immune responses equivalent to or better than traditional live or inactivated virus approaches. Furthermore, the purified recombinant proteins provide for a significantly improved safety profile. This platform technology is applicable to a wide variety of diseases including Chikungunya, Crimean-Congo hemorrhagic fever, dengue fever, Ebola, Eastern equine encephalitis, hepatitis C, influenza, Japanese encephalitis, malaria, Coronaviruses, tick-borne encephalitis, West Nile, and others. We are currently focusing our attention on the development of vaccines for several of these emerging and re-emerging viral diseases.

Hawaii Biotech’s protein production platform for developing vaccines targeting numerous infectious diseases is particularly well suited to meet the multiple requirements of safety, production yield, rapid response, and efficacy.

The Company’s vaccine technology is based on the production of recombinant proteins using stable insect cell lines. The high quality of the proteins produced in this system results in immune responses equivalent to or better than traditional live or inactivated virus approaches. Furthermore, the purified recombinant proteins provide for a significantly improved safety profile. This platform technology is applicable to a wide variety of diseases including Chikungunya, Crimean-Congo hemorrhagic fever, dengue fever, Ebola, Eastern equine encephalitis, hepatitis C, influenza, Japanese encephalitis, malaria, Coronaviruses, tick-borne encephalitis, West Nile, and others. We are currently focusing our attention on the development of vaccines for several of these emerging and re-emerging viral diseases.